Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    5 3 0 0


Joint Bone Spine
Volume 83, n° 2
pages 155-159 (mars 2016)
Doi : 10.1016/j.jbspin.2015.11.005
accepted : 4 February 2015
Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study
 

Olivier Brocq a, , Emilie Acquacalda b, Frédéric Berthier c, Christine Albert b, Gilles Bolla d, Elodie Millasseau e, Claire Destombe e, Johanna Azulay d, Caroline Asquier d, Amélie Florent b, Sylvie Le Seaux e, Liana Euller-Ziegler b
a Rhumatologie, centre hospitalier Princesse Grâce, boulevard Pasteur, 98000 Monaco, Monaco 
b Service de rhumatologie, hôpital Archet 1, université de Nice, 06200 Nice, France 
c Département d’information médicale, CHPG, 98000 Monaco, Monaco 
d Service de rhumatologie, centre hospitalier de Cannes, 06400 Cannes, France 
e Service de rhumatologie, centre hospitalier Fréjus-Saint-Raphaël, 83800 Saint-Raphaël, France 

Corresponding author.
Abstract
Objectives

To evaluate influenza and pneumococcal vaccine coverage in patients taking biological therapy for chronic inflammatory joint disease and to identify factors associated with the decision to administer these two vaccines.

Methods

Retrospective cross-sectional questionnaire study of a cohort of 584 patients taking biological therapy for chronic inflammatory joint disease (rheumatoid arthritis or spondyloarthritis). We studied the influenza and pneumococcal vaccine coverage rates, information about these vaccines given to patients by the primary-care physician and rheumatologist, and reasons for not administering the vaccines.

Results

Overall vaccine coverage rates were 44% for influenza and 62% for pneumococcus. Factors associated with being vaccinated were patient age, previous influenza vaccination, and patient information. Concern about adverse effects and absence of patient information by the primary-care physician and rheumatologist were associated with very low coverage rates.

Conclusion

This study showed insufficient vaccine coverage rates, particularly against influenza, in a population at high risk because of exposure to biological therapy. Patient information by healthcare professionals about influenza and pneumococcal vaccination has a major impact and should be renewed as often as possible.

The full text of this article is available in PDF format.

Keywords : Influenza vaccination, Pneumococcal vaccination, Biological therapy, Chronic inflammatory joint disease




© 2015  Société française de rhumatologie@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline